CPRXCatalyst PharmaceuticalsCPRX info
$21.27info-0.89%24h
Global rank4485
Market cap$2.50B
Change 7d-0.75%
YTD Performance27.29%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Catalyst Pharmaceuticals (CPRX) Stock Overview

    Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

    CPRX Stock Information

    Symbol
    CPRX
    Address
    355 Alhambra CircleCoral Gables, FL 33134United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.catalystpharma.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    305 420 3200

    Catalyst Pharmaceuticals (CPRX) Price Chart

    -
    Value:-

    Catalyst Pharmaceuticals Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $21.27
    N/A
    Market Cap
    $2.50B
    N/A
    Shares Outstanding
    117.56M
    N/A
    Employees
    82.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org